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Summary. Background: The aim of this study was to examine
whether genetic predisposition to high levels of coagulation
factors influences the risk of developing fatal and non-fatal
arterial cardiovascular events in men with a first myocardial
infarction (MI). Methods: We performed a cohort study
among 542 MI patients with a mean age of 56 years (range
32–70 years) at the time of the event. All of the men had a first
MI between 1990 and 1996 and were followed until 1
September 2004. DNA was analyzed for polymorphisms of
fibrinogen, prothrombin (factor II), factor V, factor VII and
plasminogen activator inhibitor type 1, all of which are
associated with gain of function of the protein. We collected
information from hospital files and general practitioners on
the occurrence of major arterial events. Results: In total, 254
major arterial cardiovascular events occurred during a median
follow-up period of 11 years (range 0.2–15 years). The point
estimates of the relative rates (RRs) of these events for the
variant genotypes were all between 0.7 and 1.1 except for the
prothrombin 20210A mutation: RR 1.8 (95% confidence
interval 0.8–4.1). Conclusion: These findings suggest that there
is no association between coagulation factor polymorphisms,
previously associated with plasma levels, and the risk of
recurrent cardiovascular events.
Keywords: cardiovascular disease, coagulation factor, epidemi-
ology, polymorphism.
Introduction
Most myocardial ischemic events occur through plaque
ruptures that precipitate the formation of an occluding
thrombus [1]. The growth and stability of a thrombus may
be affected by an increased activity of the coagulation system or
a decreased activity of the fibrinolytic system [2]. The associ-
ation between plasma levels of coagulation and antifibrinolytic
factors and the risk of first myocardial ischemic events has been
studied extensively.
The Northwick Park Heart Study [3] was among the first
studies to show that high levels of plasma fibrinogen, as
well as of other coagulation factors, were associated with an
increased risk of cardiovascular events. Several subsequent
studies confirmed a positive association between plasma
levels of coagulation factors and the risk of arterial
cardiovascular diseases (CVDs) [4–9]. However, studies
focussing on polymorphisms of these coagulation factors
did not find an association with CVD [10–14]. Apparently,
the observed associations between plasma levels and disease
were mainly explained by other cardiovascular risk factors.
Indeed, risks were reduced or disappeared after adjustment
for these other risk factors, and the remaining risk may well
be explained by residual confounding [5,15]. Coagulation
factor polymorphisms, which are associated with
increased plasma levels, are defined at birth and cannot be
influenced by other factors, so the causal relationship
between these factors and CVD can be studied in coagu-
lation factor polymorphisms, without confounding by
extraneous factors [16]. Recent meta-analyses suggest that
factor (F) V and prothrombin gene polymorphisms are
associated with an increased risk for CVD [17,18]. In
contrast, several multi-locus candidate gene polymorphisms
for other coagulation factors appear not, or only weakly,
associated with the risk of first myocardial infarction (MI)
[19,20]. The causal role of elevated plasma levels in CVD
remains unclear. Some have suggested that plasma levels of
coagulation factors do increase the risk for recurrent events
[9,21,22].
Correspondence: Frits R. Rosendaal, Department of Clinical
Epidemiology, Leiden University Medical Center, PO Box 9600,
2300 RC Leiden, the Netherlands.
Tel.: +31 71 5264037; fax: +31 71 5266994.
E-mail: f.r.rosendaal@lumc.nl
Received 7 August 2007, accepted 7 February 2008
Journal of Thrombosis and Haemostasis, 6: 720–725 DOI: 10.1111/j.1538-7836.2008.02930.x
 2008 International Society on Thrombosis and Haemostasis
Our aim was to examine whether genetic predisposition to
high levels of procoagulant and antifibrinolytic factors influ-
ences the risk of development of recurrent cardiovascular
events among men.
Methods
Subject population
We performed a cohort study among 560 men with a mean age
of 56 years (range 32–70 years). All men were consecutive
patients at the Leiden University Medical Center and the
Diaconessen Hospital Leiden, the Netherlands, who had a first
MI between 1990 and 1996 and were included in the Study of
Myocardial Infarction Leiden (SMILE). Details of the study
design have been reported elsewhere [11]. At baseline, all
patients completed a questionnaire concerning the presence of
cardiovascular risk factors such as smoking habits. All
questions referred to the period before the first MI. Body mass
index (BMI) was calculated by dividing weight (kg) by squared
height (m2). Medication use and history of diabetes were
retrieved fromdischarge letters from the hospital. A personwas
classified as hypertensive or hypercholesterolemic when he was
taking prescription drugs for these conditions prior to the MI.
All patients were living in Leiden or in nearby communities.
The study was approved by the Medical Ethics Committee of
the Leiden University Medical Center, and all patients gave
written informed consent.
Study endpoints
The endpoint in the present study was recurrent major arterial
cardiovascular events. We defined recurrent events as MI,
unstable angina pectoris (UAP), percutaneous transluminal
coronary angiography (PTCA), coronary artery bypass graft
(CABG) surgery and death due to coronary events. We
collected follow-up information from hospital files. When
follow-up information was missing from hospital files, infor-
mation was obtained from the patients general practitioner or
by a questionnaire sent to the patient. September 1st 2004 was
considered the end date of follow-up for those without an
event. Vital status was verified in hospital files, in municipal
registries, or by contacting general practitioners. For all
deceased patients, death certificates were requested at the
National Central Bureau of Statistics in order to obtain causes
of death. All calculations concerning causes of death are based
on this database.
MI was characterized by at least three of the following
criteria: chest pain, ischemic electrocardiogram, elevated crea-
tine kinase (CK; >170 units L)1) and CK-MB (>10% of
CK), and a positive troponin test. UAPwas characterized by at
least two of the following criteria: hospitalization due to chest
pain occurring in rest, normal cardiac enzymes, and negative
troponin test. Revascularization therapies (PTCA and CABG)
were considered as a recurrent event when the procedure took
place at least 31 days after the first MI. Causes of death were
classified into three groups according to ICD-10-CM codes:
coronary artery disease (CAD) death, codes I20–I25; other
cardiac death, codes I00–I02, I05–I09, I10–I15 or I30–I53; and
non-cardiac causes of death including all other ICD-10-CM
codes. Death from a recurrent event was defined as dying from
CAD after the first event and when no other endpoint had
occurred first.
Blood sample analysis
Amorning fasting blood sample was collected at baseline from
each participant. The median time between first MI and blood
sampling was 2.6 years (range 0.2–6.0 years). DNA was
extracted and polymorphisms were genotyped after amplifica-
tion of relevant DNA regions as described earlier [11].
Polymorphisms in six coagulation factor genes encoding
fibrinogen a and b, prothrombin (FII), FV, FVII, and
plasminogen activator inhibitor type 1 (PAI-1) were deter-
mined. Restriction enzyme digestion was used for the detection
of the a-fibrinogen gene (FGA) polymorphism TaqI (position
59855 in GB:AC107385.4; common allele coded as T1 and rare
allele as T2), the b-fibrinogen gene (FGB) polymorphisms BclI
(position 48980 in GB:AC107385.4; common allele coded as
B1 and rare allele as B2) and HaeIII [-455G/A, reference SNP
cluster identifier (rs) number 1800790; common allele coded as
H1 and rare allele as H2], and the PAI-1 promoter 4G5G
polymorphism (rs1799768). This method was also used for the
detection of the FVII polymorphismR353Q (rs6046), R coding
for arginine (353Arg) and the rare allele Q coding for glutamine
(353Gln), and for the FV Leiden mutation (G1691A, rs6025).
The detection of the G20210A allele (rs1799963) of the
prothrombin gene was performed as described previously
[23]. The PAI-1 4G5G polymorphism was analyzed in the first
331 patients who gave a blood sample.
Statistical analysis
Descriptive data are expressed as frequencies or means.
Incidence rates were calculated by dividing the number of
recurrent events (the endpoint) by the sum of the total
number of person-years each patient contributed to the
follow-up period. Person-years were calculated from the date
of diagnosis of first MI until the first recurrent event or
the last date of follow-up or end-date of study, whichever
occurred first. Cumulative survival was estimated according
to the method of Kaplan and Meier. Cox proportional
hazard models were used to determine the rate ratio for
occurrence of recurrent events according to the different
genotypes. In an additional Cox proportional hazard model
we adjusted for age, hypertension, hypercholesterolemia and
diabetes, BMI, and smoking habit at the start of follow-up.
The reference groups are homogeneous wild-type carriers
(common alleles) and the genotype associated with low
plasma levels (the FGB polymorphism BclI). SPSS for
Windows version 12.0 (SPSS Inc., Chicago, IL, USA) was
used for all statistical analysis.
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Results
A total of 560 patients were included. Five patients did not
consent to participate in the follow-up study, and another 13
patients were found to have had an ischemic event before the
initial MI. All of these patients were excluded from the present
study. Follow-up data were collected for the remaining 542
patients and only four patients were lost to follow-up: three
moved out of the country, and vital status could not be
obtained for one. Patients had a mean age of 56 years (range
32–70 years) and a median follow-up of 11 years (range 0.2–15
years). Baseline characteristics of the patients are shown in
Table 1.
Overall, 254 men out of 542 (47%) developed at least one
recurrent event. Of these 254 men, 89 (35%) developed non-
fatal recurrent MI, 60 (24%) suffered from UAP, 87 (34%)
received revascularization therapy more than 31 days after the
firstMI, and 18 (7%) died from a recurrent CAD.A total of 99
patients died during follow-up (Table 2).
The b-fibrinogen polymorphismsHaeIII andBcllI, as well as
the a-fibrinogen polymorphism TaqI, were not associated with
recurrent events – HaeIII: H1H2 relative rate (RR) 1.1 [95%
confidence interval (95% CI) 0.8–1.4], H2H2 RR 1.1 (95% CI
0.6–2.2); BclI: B1B2 RR 0.7 (95% CI 0.4–1.5), B2B2 RR 0.8
(95% CI 0.4–1.6); TaqI: T1T2 RR 0.8 (95% CI 0.6–1.0), T2T2
RR 1.0 (95% CI 0.6–1.6) (Table 3).
The prothrombin 20210A mutation appeared to be associ-
ated with recurrent events [RR 1.8 (95% CI 0.8–4.1)] for
carriers of the A-allele compared with the homozygous wild-
type genotype. Two out of six recurrent events were due to a
recurrent MI. Carriers of the FV Leiden gene polymorphism
did not have an increased risk for recurrent events [RR 1.0
(95% CI 0.6–1.6)]. FVII R353Q polymorphism was not
associated with the risk for recurrent events [353RQ RR 1.0
(95% CI 0.7–1.3); 353QQ RR 1.0 (95% CI 0.3–4.2)], nor was
carriership of thePAI-1 4G5G variant [4G5GRR 1.0 (95%CI
0.6–1.4), 4G4G RR 1.0 (95% CI 0.6–1.6)]. Adjustment for
traditional risk factors of arterial CVD did not alter these
findings.
Figure 1 and Table 4 show the survival curves of patients
with increasing numbers of high-risk coagulation factor
polymorphisms, divided into three groups. For each patient
the number of high-risk polymorphisms was calculated: the
heterozygous high-risk polymorphism counted as 1, the
homozygous high-risk polymorphism counted as 2. All patients
had two or more high-risk polymorphisms. For comparison,
the three groups were based on equal numbers of patients per
group. The first group (n = 158) consisted of patients with
zero to four high-risk polymorphisms, the second group
(n = 187) consisted of all patients with five high-risk poly-
morphisms, and the third group (n = 197) consisted of all
patients with six to nine high-risk polymorphisms. No associ-
ation was found between the number of high-risk polymor-
phisms in these patients and the occurrence of recurrent events.
Discussion
We investigated seven polymorphisms in coagulation and
antifibrinolytic factors and their association with recurrent
cardiovascular events. Except for prothrombin 20210A, none
of the polymorphisms was associated with the risk of recurrent
major arterial cardiovascular events. Because these polymor-
phisms are all associated with a gain of function (either in
plasma levels or in stability), this suggests that slightly increased
plasma concentrations of these coagulation and antifibrinolytic
factors do not increase the risk of recurrent arterial thrombosis.
Increased prothrombin levels, however, may be associated with
recurrent events.
The two b-fibrinogen gene polymorphisms BclI and HaeIII
are known to be associated with increased plasma fibrinogen
[24,25]. High fibrinogen levels have repeatedly been associated
with recurrent cardiovascular events [26]. Previous studies
found that carriership of the FV Leiden mutation [18,27,28],
the FVII 353RQ polymorphism [11,29,30], the PAI-1 4G5G
polymorphism [31] and PAI-1 plasma levels [22] may be
associated with an increased risk of a first MI. Another study
found an increased risk for cardiovascular death among
carriers of the PAI-1 4G5G polymorphism [32]. Recently,
Moss et al. [33] found, in a large cohort of 1008 carriers of
high-risk genotypes for CVD, a risk reduction of 11% for the
development of recurrent coronary events. Except for fibrin-
ogen, all associations with a first myocardial event remain
controversial, and are weak at best. In our study we did not
find an association with recurrent cardiovascular events, which
occurred at a high frequency of 47% in all men with a first MI
over a median follow-up period of 11 years.
Table 1 Baseline characteristics of 542 men with a first myocardial
infarction
n
Age, years (range) 56 (32–70)
Current smokers (%) 336 (62)
Obesity (%)* 91 (17)
Diabetes (%) 25 (5)
Hypertension (%) 96 (18)
Hypercholesterolemia (%) 12 (2)
*Obesity is defined as a body mass index exceeding 30 kg m)2. A
person was classified as having hypertension or hypercholesterolemia if
he was taking specific prescription drugs.
Table 2 Recurrent events
n (%)
Recurrent major arterial cardiovascular event 254 (47)
Non-fatal myocardial infarction 89 (35)
Unstable angina pectoris 60 (24)
Revascularization therapy 87 (34)
Fatal myocardial infarction 18 (7)
Death during total follow-up 99 (18)
Acute coronary event 29 (29)
Other cardiac causes 8 (8)
Non-cardiac causes 57 (58)
Unknown 5 (5)
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The prothrombin 20210A mutation is a major determinant
of plasma levels of prothrombin [23]. A meta-analysis
including 40 studies found that the prothrombin 20210A
mutation was associated with a 1.3-fold increased risk of a
first MI [18]. We found a similar increased risk for a recurrent
event. A previous prospective cohort study also suggested
that carriers of the prothrombin 20210A mutation may have
a worse prognosis than non-carriers after a first acute
coronary syndrome [34]. Our findings confirm this notion;
however, the findings are based on very small numbers of
patients.
The effects of single polymorphisms on the risk of recurrent
cardiovascular events may be too small to be detected in a
study with a relatively small sample size like ours. However,
most of the point estimates were close to the null effect,
suggesting that an association was truly absent. We saw no
effect of multiple carriership of high-risk coagulation factor
polymorphisms on the risk of recurrent CVD. No difference
was found in the survival of the three groups, suggesting that
even carriership of several of these high-risk polymorphisms
does not influence the prognosis of these patients.
Some may argue that we should have restricted the endpoint
to MI. We feel that all cardiovascular events in which
atherothrombosis is involved should be classified as endpoints.
Otherwise, misclassification of these events to the no-event
group would lead to the underestimation of an existing effect.
Additionally, our study population had a very long median
follow-up of 11 years, in which only four patients were lost to
follow-up, suggesting that our results were not affected by loss
to follow-up. Furthermore, this study was restricted to men
below the age of 70 years. As the median time between the first
MI and blood sampling was 2.6 years, several men dying
shortly after the first event were not included.
Table 3 Incidence and relative rate (RR) for recurrent major arterial cardiovascular events by genotype
Polymorphism Events (n) Person- years
Incidence (1000
person-years)1) RR (95% CI)
RR (95% CI)
adjusted*
FGB HaeIII
H1H1 152 2552 60 1 (ref) 1 (ref)
H1H2 93 1423 65 1.1 (0.8–1.4) 1.1 (0.8–1.4)
H2H2 9 132 64 1.1 (0.6–2.2) 1.1 (0.6–2.2)
FGB TaqI
T1T1 140 1988 70 1 (ref) 1 (ref)
T1T2 92 1808 50 0.8 (0.6–1.0) 0.8 (0.6–1.0)
T2T2 22 311 71 1.0 (0.6–1.6) 1.0 (0.6–1.5)
FGA BclI
B1B1 8 94 85 1 (ref) 1 (ref)
B1B2 75 1257 60 0.7 (0.4–1.5) 0.8 (0.4–1.6)
B2B2 171 2756 62 0.8 (0.4–1.6) 0.8 (0.4–1.6)
Prothrombin
20210GG 248 4059 61 1 (ref) 1 (ref)
20210GA 6 48 125 1.8 (0.8–4.1) 1.5 (0.7–3.5)
Factor V
1691GG 238 3838 62 1 (ref) 1 (ref)
1691AA/1691AG 16 269 59 1.0 (0.6–1.6) 1.0 (0.6–1.7)
Factor VII
353RR 200 3227 62 1 (ref) 1 (ref)
353RQ 52 854 61 1.0 (0.7–1.3) 1.0 (0.8–1.4)
353QQ 2 26 77 1.0 (0.3–4.2) 1.3 (0.3–5.1)
PAI-1§
5G5G 35 582 61 1 (ref) 1 (ref)
4G5G 81 1404 58 1.0 (0.6–1.4) 0.9 (0.6–1.4)
4G4G 43 710 61 1.0 (0.6–1.6) 1.0 (0.6–1.6)
*Adjusted for hypertension, hypercholesterolemia and diabetes before first myocardial infarction, body mass index, age at start of follow-up and
smoking. Reference category; n (1691AA) = 1, n (1691AG) = 15; §n = 331. 95% CI, 95% confidence interval; FGA, a-fibrinogen gene; FGB, b-
fibrinogen gene; PAI-1, plasminogen activator inhibitor type 1.
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Fig. 1. Kaplan–Meier curves for recurrent major arterial cardiovascular
events-free survival for three groups with increasing numbers of high-risk
coagulation factor polymorphisms. Zero to four coagulation factor
polymorphisms: n = 158, recurrent events = 71. Five coagulation factor
polymorphisms: n = 187, recurrent events = 96. Six to nine coagulation
factor polymorphisms: n = 197, recurrent events = 87.
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Anticoagulation therapy combined with aspirin after first
ischemic events decreases the risk for a second event [35]. Thus,
the lowering of vitamin K-dependent coagulation factor levels
influences the prognosis. Our baseline study population
consisted of patients who had suffered a previous MI. As a
result most, if not all, patients were treated with medication to
minimize the risk of a recurrent event. It is plausible that this
treatment modified a possible effect of plasma coagulation
factor levels on the risk of recurrent cardiovascular events. If
this is the case, the clinical relevance of determining coagulation
and antifibrinolytic polymorphisms after the first ischemic
event is low.
In conclusion, our findings suggest that polymorphisms
associated with lifelong slightly increased coagulation and
antifibrinolytic plasma levels are not associated with the risk of
recurrent cardiovascular events among men who survive a first
MI.
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